Naim Shehadeh

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Permanent Neonatal Diabetes due to Mutations in <i>KCNJ11</i> Encoding Kir6.2

Jørn V. Sagen, Helge Ræder, Eba Hathout et al. · Diabetes · 2004 · 334 citations · Full text

Liraglutide in Children and Adolescents with Type 2 Diabetes

William V. Tamborlane, Margarita Barrientos‐Pérez, Udi Fainberg et al. · New England Journal of Medicine · 2019 · 333 citations · Full text

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 317 citations · Full text

Diabetes Management, Urology, Medicine +11